Abstract: The present disclosure relates to methods of treating a tumor with a nucleotide vaccine (e.g., DNA vaccine encoding a tumor antigen) in combination with an IL-7. In some aspects, the IL-7 is administered after the administration of the nucleotide vaccine (e.g., after the peak expansion phase of the tumor-specific T cell immune response) or concurrently with the nucleotide vaccine.

Abstract: The present disclosure relates to methods of treating a disease or disorder associated with a coronavirus infection (e.g., SARS-CoV-19) in a subject, comprising administering an IL-7 protein to the subject. In some aspects, the IL-7 protein is a long-acting IL-7 protein.

Abstract: The present disclosure relates to methods of promoting the mobilization of HSCs to the peripheral blood with an IL-7 protein. In some aspects, the method further comprises administering an additional agent, such as G-CSF and/or AMD3100. In some aspects, the methods disclosed herein are useful in treating a disease or disorder associated with an abnormality of a hematopoietic process.

Abstract: The present disclosure relates to methods of treating a solid tumor with an IL-7 protein in combination with a population of modified immune cells, e.g, CAR-bearing immune cells (e.g., CAR-T cells or iNKT-CAR cells) and/or transgenic TCR-bearing immune cells.

Abstract: The present disclosure relates to methods of treating a cancer (or a tumor) with an IL-7 protein in combination with a multispecific (e.g., bispecific) antibody.

Abstract: The present disclosure relates to T cell anticancer immunotherapy based on modulation of Nrf2 expression, that is, to an Nrf2-targeting immune cell, e.g., T cell, anticancer therapy. The present disclosure allows deep interference with the Nrf2 expression in T cells, thereby solving the problem of immune tolerance shown by cancer cells to T cells; in other words, the effect of anticancer immunotherapy can be improved by targeting Nrf2. The present disclosure can provide an Nrf2-targeting new T cell anticancer immunotherapy and a T cell for the second-generation anticancer immunotherapy. This technology is applicable to the preparation of CAR-T, engineered T, and TIL T cells, and to the treatment of various solid carcinomas, including lymphoma. It can be said to be a new anticancer therapy that improves the therapeutic efficacy effectively.

Abstract: The present disclosure relates to methods of treating a cancer (or a tumor) with an IL-7 protein in combination with an immune checkpoint inhibitor, such as a PD-1 antagonist (e.g., anti-PD-1 antibody) or a CTLA-4 antagonist (e.g., anti-CTLA-4 antibody).

Abstract: Disclosed herein are therapeutic uses for treating cancer in a subject in need thereof, comprising administering to the subject a population of chimeric antigen receptor (CAR)-bearing immune effector cells and an IL-7 protein (e.g., modified IL-7 protein).